Innate Pharma S.A. (IPHA) vs LENZ Therapeutics (LENZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Innate Pharma S.A. (IPHA) has outperformed LENZ Therapeutics (LENZ) over the past year, losing 52.6% versus a loss of 90.0%. Over five years, IPHA leads with a -82.0% price change compared with -95.6% for LENZ. Innate Pharma S.A. is the larger company by market cap ($96.4 million vs $93.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IPHA | LENZ |
|---|---|---|
| Share price | $0.8634 | $2.97 |
| Market cap | $96.44M | $93.16M |
| 1-day change | -8.14% | -11.23% |
| YTD return | -50.66% | -81.47% |
| 1-year return | -52.56% | -89.97% |
| 5-year return | -82.01% | -95.57% |
| EPS (TTM) | $-0.59 | $-4.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $19.09M |
| Net income (latest FY) | — | $-82.13M |
| Gross margin | — | 97.81% |
| Operating margin | — | -477.46% |
| Net margin | — | -430.25% |
| 52-week high | $2.71 | $32.13 |
| 52-week low | $0.829 | $2.80 |
| Distance from 52-week high | -68.14% | -90.77% |
| Analyst consensus | buy | none |
| Avg. price target upside | +826.57% | +400.17% |
| Average volume | 42.76K | 892.30K |
| Shares outstanding | 111.70M | 31.42M |
| Employees | 120 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPHA has outperformed LENZ by 37.4 percentage points over the past year.
About Innate Pharma S.A.
IPHA stock →Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 120 employees
About LENZ Therapeutics
LENZ stock →LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees
IPHA vs LENZ FAQ
Which is bigger, Innate Pharma S.A. or LENZ Therapeutics?
Innate Pharma S.A. (IPHA) is larger, with a market capitalization of $96.44M compared with $93.16M for LENZ Therapeutics (LENZ).
Which stock has performed better over the past year, IPHA or LENZ?
IPHA returned -52.56% over the past 12 months, compared with -89.97% for LENZ (price return, excluding dividends). Past performance does not predict future results.
Are Innate Pharma S.A. and LENZ Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.